The Tesla Connection (found this online)
I mentioned Dr. Ed Buiel graduated in 1998 with a PHD under Dr. Jeffery Dahn.
This is the same Dr. Jeffery Dahn who recently signed an exclusive contract with
Tesla. Dr. Dahn has been working to increase the performance of the company’s
(already cutting-edge) batteries since June 8, 2016.
Coulometrics is an advanced energy storage consulting and manufacturing
company. It provides cell assembly and testing services for LIB, EDLC, NiMH, and
lead acid batteries. It also provides mixing, coating, calendaring, and slitting services
for battery companies.
It doesn’t take a lot of digging to figure out that the company that can most efficiently
work through the qualification process and have ready material to provide will benefit
from a friendly introduction to not only Tesla, but the many potential customers
who are looking for a stable, diversified supply outside of China.
The European Commission and Europe’s major companies are investing strongly
into renewable energy generation, efficient energy storage, and the light-weighting
and electrification of transport. They want a local source. I believe Leading Edge
Materials is uniquely positioned to provide it.

Bought this last week. Long

Delisting is usually not a good thing.

MTIA.....Who are they. Bai Ge,seems to be the Managing Director, owner, salesperson, and staff. Can someone out there show something about this company. ANYTHING

Berkshire Hathaway To Purchase North American Palladium (PAL) Within 90 Days Ventures Sierra Equity
Latest Projections: Berkshire Hathaway To Purchase North American Palladium (PAL) Within 90 Days Ventures Sierra Equity. Shares of PAL finished higher up over 18% during Wednesday's session. Check back as Sierra follows her leads, look for the official news, when it breaks remember Sierra called this first!

Win win for Goldberg and CO. Shareholders like usual lose.

someone is going to buy this pup PAL... (China loves rare metals) autos=palladium prices to soar

Bought in the 2.40's, and 2.50's and today.

ECTE threw a bone to shareholders, the good news is the Board is with Platinum.

BooDog, Last week I called ECTE and spoke to a receptionist who i.d. herself as Genevieve. Spoke to this woman 4x. Every time got the same answer "Christine O. not in but you can leave a v.m. or send her an e-mail". I told her i'm a shareholder and Christine has not responded. Her response was Christine has been at clinical trials and overloaded with I.R. calls. I asked her how are the meetings going with Platinum....response."I REALLY HOPE THEY ARE GOING WELL" Same kind of response from Platinum. Obviously none of them can or will reveal the contents of these meetings. Here is my 2 cents: I think before anything was discussed about Platinum's proposal, -Platinum / Goldberg & ECTE/ Board had to repair their business relationship with each other. Lunch-Dinner -Conference- Then into the proposal. No doubt like all stips and agreements there will be a give and take on both sides. Plus you would think ECTE would want discovery -evidence that what Goldberg offers comes to fruition. Then the lawyers from each party will have to go over agreement. Time consuming process. One thing we do know if ECTE turned offer totally down Goldberg would be ripping them another a## publically. IMO we get a positive P.R. shortly. G/L

Maybe if you call Joseph Finestone at Platinum you will get that the meetings are still ongoing....g/l . Christine not calling back or emailing.

Maybe we get an update today.

meetings still in progress. Friday seems like a perfect day for a P.R.

Sometimes u have to be in the right place at the right time, this is both.

Wow , how the "F" did i miss this one----getting in now--g/l

Stll holding holding long and strong here. Should be interesting on how the sales team #S look....

Paulness, If this company comes out with news on stem cell advancement and its ground breaking i beg to differ--we will see the pps sky rocket to over 2-3 bucks easily and probably keep on going. 3x the pps in 5 minutes---lets hope

P.R. - AVNR ringing the bell on the NASDAQ, added was the launch --in FEB ---no delay.

soon--next p.r on launch, imo

Zacks Einsteins gave reason for downgrade, per: some analysts feel the next qter will result in a 0.14 loss--DUH, anyone following AVNR knows profits should come later on in 2011, besides that the potential of Nuedexta should result in an increase of pps, {and look for a possible takeover} you know when i see this horse--bleep it gets me sick because it shows no D-D on their part at all except a few analysts predictions for next qter-- bottom line --how can you short this when explosive news around the corner. bring it on

btw other PHARMAS are watching AVNR launch like a hawk--i still feel someone out there like a TEVA will make a bid for them, {imo} just a reminder CEO said many Pharmas had interest before approval --and CEO did say Avnr will do launch by themselves--guarantee many are in talks with them---if any of these type talks leak --8 bucks plus in a day. g/l

Gambling fools--thats who---they are betting on a delay of launch or Avnr needs more $ for launch--aint happening---. 3.38 200 mda --not going back there. Nuedexta is already in the data bases of major retail pharmacy chains---Doctors want this drug for their patients yesterday. more shorts equals EXPLOSION of pps . g/l

To top it off ZACKS ON THE 11TH PUT A DOWNGRADE --UNDERPERFORM --{what B.S} The gurus at Zacks have no clue--its a technical underperform by ZACKS because of the short sellers they see and knowing more expenses then usual by the next Quarter will be seen because of Nuedexta launch---SO WHAT is ZACKS saying pps hits 10 bucks instead of 15 --15 instead of 20, ZACKS HAD NO EFFECT ON PPS and will eventually change back to neutral or out perform when they see pps climbing with the potential sales of the "ONLY " PBA drug approved out there by the FDA---launch news and BTW ZACKS GAVE NO REASON --LOL

As Avanir's (AVNR) February 2011 commercial launch of Nuedexta fast approaches, the company seems to be well positioned to hit the ground running. Avanir's recently assembled yet experienced sales force seems to be congealing nicely, as evidenced by some of the posts by its members on the Avanir specific message board at CafePharma.com, a forum in which employees of pharma companies may anonymously share sentiment and concerns (and generally vent) with regard to their respective employers.

Nuedexta has been confirmed to be in the drug data bases of many major pharmacies, such as CVS, and will soon be ready for distribution. Additionally, major group and individual health plans have already quoted co-pay pricing for Nuedexta. My Blue Cross HMO plan gave a co-pay quote of $60 for a three month supply (90 pills). Another traders plan gave a quote of $340 for a three month supply. I would imagine most plans will land somewhere in between. A small price to pay when one considers the debilitating affect PBA has on ones social/family life.

On a related note, a new survey was recently released (presumably in effort to create PBA awareness) detailing data concerning the aforementioned debilitating impact of PBA (see here).

Avanir has yet to tip their hat concerning plans to seek EMA approval, nor have they provided any updates since their 11/01/10 conference call concerning talks with potential EU partners. Avanir has not yet responded to my recent inquiries into such. There has been healthy debate among investors as to which Avanir should pursue first, EU approval or an EU partnership. Whichever Avanir decides, the news would certainly give Avanir's share price a boost, if Nuedexta's US sales doesn't do that first.

It is becoming evident that the market for Avanir's drug and/or the companys ability to deliver on sales are currently being underestimated by analysts and Wall Street alike as Avanir closed yesterdays regular trading session at $4.26, which is just above it's 50 day EMA and nearly 27% below it's 52 week high. I suspect Wall Street's general "show me the money" sentiment towards Avanir will change once institutions and hedge funds begin tracking Nuedexta's weekly prescription data.

With plenty of cash on hand, no competition, new indications to pursue, and a pipeline to develop, Avanir appears to be in the driver's seat and in complete control. Provided that their sales and marketing strategies are well executed, there seems to be little to prevent them from becoming a successful commercial enterprise and providing shareholder value for years to come
1/9/10 by Wilkinson ------ALPHA---- SAME ARTICLE AS POST BEFORE

Oregon, this is just heating up. g/l

Since you brought up Celegene on AVNR board --why hasnt ceo here made a press release about the 13 mill and he stated wont do it at this time-- it would be nice to know what kind of deal MMRF has with Celegene if any with that data. btw--my kid bought some here and just wondering also why the low volume with pretty good news recently.

Shares of Avanir Pharmaceuticals Inc (NASDAQ: AVNR) crossed above its 50-day moving average on Thursday. The stock has a 50-day moving average of $4.20 and last traded at $4.26

Thats why im an advocate of AVNR having a very good chance of getting bought out- {its excellent AVNR says they will do it alone}--{always look out the box}--and at a very high and unexpected price. Remember besides being the only PBS drug approved Avnr has stated on numerous occassions many pharmas interested and due to the fact many of their patent drugs are expiring -----WIN --WIN, just cant get any better.

What i would like to know--Celegene buys data for 13 mill--if drug goes to FDA eventually and gets approved does MMRF get a cut.

PPS should start heading north by the end of this month. News of the intiation of the selling by sales force in Feb. should push pps into 6 buck range, then i still believe we hear of a Pharma very interested in AVNR---either way with PBS drug and other at 3 phase and possible FDA approval 10 bucks is far behind.

TEX--imo opinion--this pps will explode. Alot happening after FDA approval.

I still think AVNR will be taken over.--no matter what they say. Been buying on the dips below 4 bucks, pps should be heading back to the 4.40 plus range for the time being. g/l to all and happy holidays. Dakota

Not Rich, Even though Avnr is going through the motions after approval --and they seem to be doing a good job --however--no matter what they say today--i still believe a big Pharma is licking their chops---Main reason Nudexta is the only drug approved for PBA --many Pharmas-Bios patents are running out--and remember these buy-outs always come as a surprise, Avnr may be doing some the dirty work by getting the launch in place but for 2011 this could be a score for a company like TEVA--etc. and AVNR shareholders----if im wrong the wait will be fine also. g/l

Avanir is expected to announce their next earnings report on Nov. 30th, 2010, and from there the market may get more information regarding pricing for their drug, establishment of sales network and infrastructure, and time-line for first product shipments or pre-orders. Once this data is provided the market should have a much clearer perspective of future valuation, which in-turn would then clear any larger companies to start placing any possibly bids on the company. BUY OUT rumors should be hitting the street shortly---read between lines--during conference call of approval CEO said many companies interested. Then all of a sudden they announced stock offering and company will complete launch themselves.{jeffries} IMO i really think a bigger cash rich PHARMA is already running the show----Now besides the original 40 plus million AVNR has they now HAVE another 80 mill in cash--- BUY-OUT victor can immeadiatly use their sales staff and launch quicker--$$$$--for their 2011 revenue---PATENTS RUNNING OUT ON MOST---- and AVNR top brass all took raises and bonuses after approval---------wouldnt it be sweet a few fight for this one--$$$$

NEW YORK (Market Intellisearch) -- Unusual volume of put contracts was traded today. There were 6,677 puts contracts versus the ten day average volume of 1,626. On the calls side, 2,407 calls contracts were traded. Today's traded Put/Call ratio is 2.77. There were 2.77 puts traded for each call contract.

I doubt this is inst investors, shorts coming back here--thats ok --they got burnt once and will again-----some hedging going on to buy at lower price on WED.-Thursday---well all week and Friday hung in there. Im not sure but i think on the 24th or sometime next week QTER results. HOWEVER MORE PUTS USUALY MEAN A BOTTOM --AND IMO THIS IS IT ----USUALLY A A BIG BOUNCE IN THE COMING WEEKS OR MONTHS--WITH THAT SAID--OVER 90PCT OPTION TRADERS AT THE END OF THE YEAR ARE LOSERS. I always said no one can predict price movement with out having inside info --ESPECIALLY HERE with an FDA APPROVAL AND POSSIBLE TAKEOVER TARGET.

AGREE--EOM

Slow and Sweet, Nice d-d, With AVP-923 on the cusp of another FDA approval also treating PBA ---even with the 20 million shares @4.40- {for launch}-you just have to believe since AVNR has the only drug approved to treat PBA ----TAKEOVER TARGET. I keep going back to conference call --Many interested partys---even Prospectus says possible partnership with AVP-923-----IMO even if AVNR is bent on doing it all alone on the launch --someone [PHARMA} out there are licking there chops on this one--- All it takes right now is one leak --soon

G/L KEI, i think with patience we score here.

Most analysts who are looking for AVNR to hit 10-20 bucks also add Possible Takeover--havent seen any of them say other wise since--LONG AND STRONG

I saw what Brumley said in his newletter--every he says is correct and suggests with this stock offering AVNR will go about the launch themselves----this is my take--nothing rarely happens the way it seems it should in the wild west of trading---Patents running out or gone by many BIOS-PHARMAS---Still think with the admittance by AVNR of multiple interested Companies --AVNR will be a TAKEOVER TARGET during or before launch. $$$$$$ imo